LINC01410 antisense oligonucleotide

LINC01410 antisense oligonucleotide is a gapmer antisense oligonucleotide (ASO) designed to target and knock down the long non-coding RNA (lncRNA) LINC01410. Developed primarily in a research context by the Dana-Farber Cancer Institute, this therapeutic candidate is being investigated for the treatment of multiple myeloma (MM). LINC01410 is overexpressed in MM patient cells and acts as a key dependency for tumor cell growth. By binding to LINC01410, the ASO triggers RNase H-mediated degradation of the transcript. This knockdown disrupts LINC01410's interaction with the minichromosome maintenance (MCM) complex (specifically subunits MCM4, MCM5, and MCM7), which is essential for DNA replication and cell cycle progression. Consequently, treatment with the ASO leads to cell cycle arrest, downregulation of cyclins (CCND1, CCND2, CCND3), and induction of apoptotic cell death in multiple myeloma cells.

Other names

LINC01410 ASOLINC-01410 ASOLINC 01410 ASOLINC01410 gapmerLINC-01410 gapmerLINC 01410 gapmerLINC01410 gapmer antisense oligonucleotideLINC-01410 gapmer antisense oligonucleotideLINC 01410 gapmer antisense oligonucleotide